Lupus is an autoimmune disorder wherein the immune system of the body attacks body’s own healthy tissues and organs, resulting in swelling, tissue damage, and pain. The inflammation caused by lupus can affect the joints, kidneys, brain, blood cells, skin, heart, and lungs. The exact cause of lupus is unknown, however, certain risk factors are associated with lupus. These risk factors include hormones, genetics, smoking, viral infection, and others. Some of the common symptoms related to lupus include fatigue, muscle and joint pain, fever, mouth ulcers, headaches, arthritis, malar rash, unusual hair loss, and others. Diagnosis of lupus is difficult as its symptoms mimic those of other ailments such as rheumatoid arthritis, scleroderma, etc. However, a butterfly-shaped rash, also known as malar rash across the nose and cheek is a highly distinctive feature of lupus. There are other complications that can arise from lupus, such as urinary tract infections, yeast infections, herpes, pregnancy loss, bone tissue death, and others.
Market Dynamics
The high prevalence and incidence of lupus, rapid research and development activities towards development of novel therapeutics for treatment of lupus, and increasing adoption of inorganic growth strategies such as acquisitions and collaborations by key players operating in the market are the major factors that are expected to drive growth of the global lupus therapeutic market over the forecast period.
For instance, according to an article published by the Lupus Science and Medicine journal, in April 2021, it is estimated that the incidence and prevalence of Systemic Lupus Erythematosus (SLE) were around 0.3 to 5.1 per 100 000 per year and 6.5 to 85 per 100 000 population, respectively in Europe in 2020.
Key features of the study:
- This report provides an in-depth analysis of the global lupus therapeutic market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global lupus therapeutic market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
- Key companies covered as a part of this study include Hikma Pharmaceuticals PLC, Lupus Therapeutics, Dr. Reddy's Laboratories Ltd., GlaxoSmithKline plc, Amgen Inc., Novartis AG, Sanofi, UCB S.A., ImmuPharma PLC, Bayer AG, Merck & Co., Inc., Aurinia Pharmaceuticals Inc., Pfizer Inc., ADMA Biologics, Inc., AstraZeneca, F.Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, and Boehringer Ingelheim International Gmbh
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global lupus therapeutic market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global lupus therapeutic market
Detailed Segmentation:
- Global Lupus Therapeutic Market, By Disease Type:
- Systemic Lupus Erythematosus (SLE)
- Cutaneous Lupus Erythematosus
- Drug-Induced Lupus Erythematosus
- Neonatal Lupus
- Global Lupus Therapeutic Market, By Treatment Type:
- Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
- Biologics
- Antimalarial Drugs
- Corticosteroids
- Others (Disease-Modifying Anti-Rheumatic Drugs, Anticoagulants, among others)
- Global Lupus Therapeutic Market, By Route Of Administration:
- Oral
- Subcutaneous
- Intravenous
- Others (Intramuscular, Intradermal, among others)
- Global Lupus Therapeutic Market, By End User:
- Hospitals & Clinics
- Diagnostic Laboratories
- Others (Homecare, Specialty Centre, among others)
- Global Lupus Therapeutic Market, By Region:
- North America
- Latin America
- By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- By Country
- GCC
- Israel
- Rest of Middle East
- Africa
- By Country/Region
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Hikma Pharmaceuticals PLC*
- Company Overview
- Material Portfolio
- Financial Performance
- Key Highlights
- Market Strategies
- Lupus Therapeutics
- Dr. Reddy's Laboratories Ltd.
- GlaxoSmithKline plc
- Amgen Inc.
- Novartis AG
- Sanofi
- UCB S.A.
- ImmuPharma PLC
- Bayer AG
- Merck & Co., Inc.
- Aurinia Pharmaceuticals Inc.
- Pfizer Inc.
- ADMA Biologics, Inc.
- AstraZeneca
- F.Hoffmann-La Roche Ltd
- Bristol-Myers Squibb Company
- Teva Pharmaceutical Industries Ltd.
- Takeda Pharmaceutical Company Limited
- Boehringer Ingelheim International Gmbh
“*” marked represents similar segmentation in other categories in the respective section.
